Probiotics may tame cancer Drug's gut side effects
NCT ID NCT06892093
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking probiotics can prevent severe diarrhea in women with HER2-positive breast cancer who are treated with neratinib. About 308 participants will be randomly assigned to receive either probiotics or a placebo for six weeks, alongside standard diarrhea prevention medication. The goal is to see if probiotics reduce the severity and frequency of diarrhea, helping patients stay on their cancer treatment with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Probiotics (dietary supplement)
- What this could lead to
- If it works, this could offer a simple, safe way to prevent severe diarrhea in breast cancer patients taking neratinib, improving their quality of life.
- What could go wrong
- This is an early-stage trial with no phase designation, so results are uncertain. Probiotics may not reduce diarrhea, and individual responses can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIARRHEA CAUSED BY DRUG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?